Treatment-resistant bipolar disorder

Abstract

Despite the remarkable increase in medications validated as effective in bipolar disorder, treatment is still plagued by inadequate response in acute manic or depressive episodes or in long-term preventive maintenance treatment. Established first-line treatments include lithium, valproate and second-generation antipsychotics (SGAs) in acute mania, and lithium and valproate as maintenance treatments. Recently validated treatments include extended release carbamazapine for acute mania and lamotrigine, olanzapine and aripiprazole as maintenance treatments. For treatment-resistant mania and as maintenance treatments, a number of newer anticonvulsants, and one older one, phenytoin, have shown some promise as effective. However, not all anticonvulsants are effective and each agent needs to be evaluated individually. Combining multiple agents is the most commonly used clinical strategy for treatment resistant bipolar patients despite a relative lack of data supporting its use, except for acute mania (for which lithium or valproate plus an SGA is optimal treatment). Other approaches that may be effective for treatment-resistant patients include high-dose thyroid augmentation, clozapine, calcium channel blockers and electroconvulsive therapy (ECT). Adjunctive psychotherapies show convincing efficacy using a variety of different techniques, most of which include substantial attention to education and enhancing coping strategies. Only recently, bipolar depression has become a topic of serious inquiry with the dominant controversy focusing on the place of antidepressants in the treatment of bipolar depression. Other than mood stabilizers alone or the combination of mood stabilizers and antidepressants, most of the approaches for treatment-resistant bipolar depression are relatively similar to those used in unipolar depression, with the possible exception of a more prominent place for SGAs, prescribed either alone or in combination with antidepressants. Future work in the area needs to explore the treatments commonly used by clinicians with inadequate research support, such as combination therapy and the use of antidepressants as both acute and adjunctive maintenance treatments for bipolar disorder. With the first report of lithium's efficacy in 1949 by Cade, bipolar disorder has the longest record of treatment efficacy among the major Axis I disorders. Furthermore, after more than half a century of clinical research, multiple agents from many different pharmacological classes have shown at least some efficacy, while many other agents (albeit without a consistent database demonstrating their utility) are prescribed regularly by clinicians. Yet, despite this plethora of choices, treatment of bipolar disorder remains suboptimal from the points of view of clinicians and patients alike. Whether measured by recovery time from manic or depressive episodes or preventive efficacy of maintenance treatments, bipolar disorder is characterized by sluggish responses, inadequate responses, poor compliance and recurrences in controlled cli...

Chronic Lithium Salt Treatment Reduces CRE/CREB-Directed Gene Transcription and Reverses Its Upregulation by Chronic Psychosocial Stress in Transgenic Reporter Gene Mice

“…Lithium salts exert two therapeutic effects: an acute antimanic action and a delayed mood-stabilizing and phase prophylactic action, which requires chronic treatment of up to several months (Gitlin, 2006). The latter one is assumed Figure 4 Effect of lithium on CREB Ser 133 phosphorylation.…”

“…However, in addition, particularly environmental influences such as chronic stress are assumed to precipitate the disease (Johnson, 2005). Among the drugs recommended for the treatment of bipolar disorder, lithium salts are of prime importance (Gitlin, 2006). Lithium has been discovered more than 50 years ago as a drug with an acute antimanic action (Cade, 1999).…”

Mood stabilizers commonly restore staurosporine-induced increase of p53 expression and following decrease of Bcl-2 expression in SH-SY5Y cells

“…Although mood stabilizers such as lithium (Li), valproate (VPA), carbamazepine (CBZ), and lamotrigine (LTG) are commonly used for treatment of BD patients (Goodwin, 2003), their effects are often inadequate. Moreover, many BD patients have suffered from pervasive and chronic symptoms, multiple episode recurrences and marked functional disability (Giltin, 2006).…”

Should bipolar disorder treatment be modified depending on staging?

“…A systematic review that included 15 clinical trials showed that clozapine was associated with improvement in social functioning [23]. It is worth mentioning that clozapine may be also effective for treatment-resistant patients with bipolar disorder [23][24][25]. Despite proven effectiveness in bipolar disorder, there are concerns regarding some significant side effects, including agranulocytosis, myocarditis, cognitive disturbances, and weight gain.…”